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Abstract
Introduction: Although different scores have been suggest-
ed to predict outcomes in the setting of upper gastrointesti-
nal bleeding (UGIB), few comparative studies between sim-
plified versions of older scores and recent scores have been 
published. We aimed to evaluate the accuracy of pre- (PreRS) 
and postendoscopic Rockall scores (PostRS), the Glasgow-
Blatchford score (GBS) and its simplified version (sGBS), as 
well as the AIMS65 score in predicting different clinical out-
comes. Methods: In this retrospective study, PreRS, PostRS, 
GBS, sGBS, and AIMS65 score were calculated, and then, ar-
eas under the receiver operating characteristic curve were 
used to evaluate the performance of each score to predict 
blood transfusion, endoscopic therapy, surgery, admission 
to intensive/intermediate care unit, length of hospital stay, 
as well as 30-day rebleeding or mortality. Results: PreRS, 
PostRS, GBS, and sGBS were calculated for all the 433 includ-
ed patients, but AIMS65 calculation was only possible for 315 
patients. Only the PreRS and PostRS were able to fairly pre-
dict 30-day mortality. The GBS and sGBS were good in pre-
dicting blood transfusion and reasonable in predicting sur-
gery. None of the studied scores were good in predicting the 
need for endoscopic therapy, admission to intensive/inter-
mediate care unit, length of hospital stay, and 30-day re-
bleeding. Conclusions: Owing to the identified limitations, 
none of the 5 studied scores could be singly used to predict 
all the clinically relevant outcomes in the setting of UGIB. The 
sGBS was as precise as the GBS in predicting blood transfu-
sion and surgery. The PreRS and PostRS were the only scores 
that could predict 30-day mortality. An algorithm using the 
PreRS and the sGBS as an initial approach to patients with 
UGIB is presented and suggested.
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Resumo
Introdução: Apesar dos vários scores propostos para pre-
ver os diferentes outcomes no contexto de hemorragia di-
gestiva alta (HDA), poucos estudos se debruçaram sobre 
a comparação entre eles. Este estudo avaliou o desem-
penho dos scores de Rockall pré- (PreRS) e pós-endoscópi-
co (PosRS), Glasgow-Blatchford (GBS) e a sua versão sim-
plificada (sGBS), bem como o score AIMS65 na previsão de 
diferentes outcomes clínicos. Métodos: Neste estudo ret-
rospetivo, foram calculados os scores PreRS, PosRS, GBS, 
sGBS e AIMS65 e posteriormente as respectivas áreas sob 
as curvas de ROC para avaliar a capacidade de cada score 
em predizer necessidade de suporte transfusional, tera-
pêutica endoscópica, cirurgia, admissão em unidade de 
cuidados intensivos/intermédios, tempo de internamen-
to, bem como recidiva hemorrágica ou morte aos 30 dias. 
Resultados: Em todos os 433 doentes incluídos foram cal-
culados os scores PreRS, PosRS, GBS, sGBS, mas o cálculo 
do score AIMS65 apenas foi possível em 315 doentes. Ape-
nas o PreRS e o PosRS foram capazes de prever de forma 
aceitável a mortalidade aos 30 dias. O GBS e o sGBS apre-
sentaram uma boa capacidade de prever necessidade de 
transfusão e razoável capacidade para prever cirurgia. Ne-
nhum dos cinco scores foi bom a predizer a necessidade 
de tratamento endoscópico, internamento em unidade 
de cuidados intensivos/intermédios, tempo de interna-
mento ou recidiva hemorrágica aos 30 dias. Conclusões: 
Devido às limitações identificadas, nenhum dos scores 
pode ser usado isoladamente na previsão dos diferentes 
outcomes no contexto de HDA. O sGBS é tão preciso como 
o GBS na previsão da necessidade de transfusão ou cirur-
gia. Apenas os scores PreRS e PosRS são capazes de prever 
mortalidade aos 30 dias. É sugerido um algoritmo para a 
abordagem inicial de doentes com HDA usando os scores 
PreRS e sGBS. © 2018 Sociedade Portuguesa de Gastrenterologia 
Publicado por S. Karger AG, Basel
Introduction
Upper gastrointestinal bleeding (UGIB) is a common, 
potentially life-threatening condition and remains the 
most common medical emergency managed by gastroen-
terologists. It has an incidence of about 100 per 100,000 
adults per year, accounts for more than 300,000 annual 
hospital admissions in the United States, and can result 
in death in up to 15% of the cases [1–3]. 
Recent guidelines recommend risk assessment as an 
initial step in the management of patients with UGIB for 
early stratification of low- and high-risk patients, allow-
ing timely and appropriate interventions, which may 
consequently decrease morbidity and mortality [4]. With 
adequate risk assessment tools, it is possible not only to 
predict which patients are at risk of adverse events, such 
as rebleeding or death, but also to guide management de-
cisions, such as time to endoscopy, length of hospital stay, 
and level of care [5].
Several prognostic and risk scoring systems, such as 
the Rockall score (RS) [6], the Glasgow-Blatchford score 
(GBS) [7], and the AIMS65 score [8], have been devel-
oped to predict outcomes in the UGIB setting. The RS is 
one of the most commonly cited scores, which includes a 
clinical and an endoscopic component, and has been 
originally suggested as a tool to predict mortality [6]. 
Some years later, the GBS was established as an instru-
ment to evaluate the need for medical intervention (i.e., 
blood transfusion, therapeutic endoscopy or surgery), 
without including endoscopic data [7]. Yet, as this score 
contains some subjective components that may preclude 
its accurate use, a modified version has been recently pub-
lished [9]. Additionally, the AIMS65 is another modern 
and simpler risk score, composed of easy-access param-
eters, which was created with the aim to increase adher-
ence to risk stratification and to facilitate earlier triage 
and goal-directed treatment [8].
As UGIB is a medical emergency requiring timely de-
cisions, it is important that physicians know exactly which 
risk scores are reliable for each clinical outcome. How-
ever, with the advent of new scores and variations of old-
er ones, that task can be time-consuming, leading to poor 
adherence to risk stratification in the routine clinical 
practice.
The aim of this study was to compare 5 different risk 
scores used to evaluate patients presenting with UGIB, 
namely to assess their performance in predicting 7 differ-
ent clinical outcomes: admission to intensive or interme-
diate care unit, blood transfusion, endoscopic therapeutic 
intervention, surgical treatment, length of hospital stay, 
and 30-day rebleeding and mortality.
Methods
Study Design and Patients’ Selection
Data from adult nontrauma outpatients who consecutively 
presented to the emergency department (ED) of our center for 
UGIB and received endoscopic evaluation between January 1, 
2012, and December 31, 2015, were retrospectively collected. 
UGIB was defined as hematemesis, “coffee-ground” vomit, mele-
na, hematochezia with suspected bleeding from the upper gastro-
intestinal tract or detection of coffee-ground-like substance, or 
blood from a nasogastric tube. All UGIB cases were included, in-
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dependently of the bleeding source (variceal or nonvariceal). Pa-
tients younger than 18 years old, whose source of bleeding was the 
lower or middle gastrointestinal tract, who received any treatment 
at another institution, or who visited the ED due to rebleeding 
from a previous UGIB episode were excluded from this study. The 
study was approved by the local ethics committee. Since the study 
was retrospective and the study subjects were anonymized, the eth-
ical committee waived the necessity for written consent from the 
patients.
Analyzed Variables
Data were collected from medical records and included pa-
tients’ age and gender, type of presentation of bleeding, history of 
syncope, comorbidities (namely hepatic disease, cardiac failure, 
ischemic heart disease, renal failure, disseminated neoplasia, or 
any other major comorbidity), vital signs and mental status at ad-
mission, and laboratory values (i.e., hemoglobin, urea, albumin, 
and international normalized ratio [INR]). When multiple vital 
signs or laboratory tests were available from the ED, the most 
anomalous values were collected. Endoscopic diagnosis, stigmata 
of recent bleeding, and length of hospital stay were also included 
in the database. Similarly to other studies, hepatic disease was con-
sidered when patients had known history, or clinical and laborato-
rial evidence, of chronic or acute liver disease, while heart failure 
was defined as known history, or clinical and echocardiographic 
evidence, of cardiac failure [10]. Ischemic heart disease was said to 
be present if there was a past history of myocardial infarction, sta-
ble and unstable angina, or coronary intervention. Renal failure 
was defined as patients with an estimated glomerular filtration rate 
< 60 mL/min for ≥3 months calculated using the Modification of 
Diet in Renal Disease Study equation. Disseminated neoplasia was 
considered in patients who have cancer that has spread to one or 
more sites in addition to the primary site or in whom the presence 
of metastases suggests that cancer is widespread, fulminant, or 
near terminal. Altered mental status was defined as Glasgow Coma 
Scale of ≤14 or a physician-charted designation of “disoriented,” 
“lethargy,” “stupor,” or “coma” [8]. 
Scores in UGIB
In this study, 5 different proposed scores used for the evalua-
tion of patients with UGIB were compared. The pre-endoscopic or 
clinical RS (PreRS) includes age, presence of shock, and comor-
bidities to stratify patients from 0 to 7 points. This score can be 
further complemented with endoscopic data, namely endoscopic 
diagnosis and stigmata of recent hemorrhage, resulting in the 
postendoscopic or complete RS (PostRS), which scores patients 
with a maximum of 11 points (Table 1). The GBS includes only 
clinical and laboratory but not endoscopic variables, while the sim-
plified GBS (sGBS) avoids the subjective or difficult-to-define 
components of the original GBS, namely melena, syncope, hepatic 
disease, or heart failure (Table 1) [9]. The GBS and sGBS are scored 
up to 23 or 16 points, respectively. The AIMS65 comprises 5 clin-
ical and laboratorial parameters, each corresponding to 1 point 
(Table 1). As serum albumin is a laboratory parameter that is not 
always ordered when patients are being evaluated in the ED, the 
calculation of the AIMS65 score was only possible in 315 patients.
Clinical Outcomes
During hospitalization, clinical outcomes, such as blood trans-
fusion, therapeutic endoscopic intervention, admission in inter-
mediate or intensive care unit, length of stay, and surgery, were 
analyzed. The decision of transfusion was made by the attending 
physician, following local ED transfusion protocols. Therapeutic 
endoscopic intervention included one or more of the following 
hemostatic strategies: use of hemoclips, argon plasma coagulation, 
endoscopic band ligation, sclerotherapy, cyanoacrylate injection, 
or multipolar electrocoagulation, with or without previous injec-
tion of epinephrine. Length of hospital stay was divided into short 
and long, when patients were admitted for < 7 or ≥7 days, respec-
tively. Need for surgery was defined as the need to undergo lapa-
rotomy after the first or second endoscopy had failed to secure the 
UGIB episode. After discharge, patients were referred to the out-
patient clinics and were followed up for a minimum of 30 days. 
During the follow-up, 30-day rebleeding and mortality were eval-
uated. Rebleeding was defined as recurrent hematemesis, melena, 
or both with either shock or a decrease in hemoglobin of at least 
2 g/dL after initial treatment and stabilization. Mortality was de-
fined as death occurring within 30 days of hospital admission.
Statistical Analysis
Descriptive analysis of the results was performed using the Sta-
tistical Package for the Social Sciences (SPSS) software, version 
22.0 (IBM, Armonk, NY, USA). Continuous variables were ex-
pressed as means ± standard deviations or medians and interquar-
tile ranges (IQR), when normal or non-normal distributions of 
data were found, respectively. Categorical variables were expressed 
as absolute frequency (number) and relative frequency (percent-
ages). The accuracy of each risk score to predict clinical outcomes 
was evaluated by the area under the receiver operating character-
istic (AUROC) curve with 95% confidence interval (CI). An AU-
ROC of 0.9–1 indicates an excellent predictive power, while an 
AUROC of 0.8–0.9, 0.7–0.8, 0.6–0.7, and 0.5–0.6 represent good, 
fair, poor, and failed predictive power, respectively. Comparison 
of different scores’ prognostic accuracy was performed using the 
method described by Hanley and McNeil [11]. In each curve, 
Youden index J, the point on the ROC curve that is farthest from 
the line of equality (diagonal line), is represented. A p value of 0.05 
was considered statistically significant.
Results
Characterization of Patients and UGIB Episodes
During the studied period of time, a total of 433 episodes 
of UGIB were identified and selected for analysis. Almost 
two-thirds (64.9%) of the patients were male, and the me-
dian age was 67.8 years (IQR: 56.0–80.0). At admission, me-
lena alone was the most common presentation of UGIB (in 
46.2% patients), while hematochezia was rare (2.8%). Syn-
cope was reported by about one-tenth of patients. Heart 
failure and liver disease were the most common comorbid-
ities, being present in 21.9 and 19.6% of the patients, respec-
tively. Regarding medication, more than one-fourth of the 
patients (27.5%) were taking proton pump inhibitors when 
the bleeding episode occurred. Acetylsalicylic acid, nonste-
roidal anti-inflammatory drugs, anticoagulants, and other 
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antiplatelet agents were used in 27.7, 17.3, 17.3, and 10.4%, 
respectively. Patients presenting with tachycardia were 
common (in 26.6%), but hypovolemic shock was present in 
only 16.4% of the cases. Laboratory results and detailed pa-
tient characteristics are shown in Table 2.
After upper endoscopy, the 3 most frequent sources of 
bleeding were gastric ulcers, esophageal varices, and duo-
denal ulcers, accounting for 16.9, 15.2, and 14.8% of the 
endoscopic diagnosis, respectively. Upper endoscopy was 
unrevealing in almost one-fifth (17.8%) of the patients. A 
full list of endoscopic findings and respective frequencies 
can be found in Table 2.
Risk Score Calculation and Distribution
Using the collected data, the 5 risk scores described in 
the Methods section were calculated. Data for the calcula-
tion of the PreRS and PostRS were available for all pa-
tients. The mean calculated PreRS was 3.3 ± 1.6, while the 
PostRS was 4.4 ± 1.8. Calculation of the GBS and sGBS 
was possible in all patients as well. The mean values were 
11.6 ± 3.7 for the GBS and 10.0 ± 3.3 for the sGBS. The 
mean value of the AIMS65 score was 1.7 ± 1.0. 
Table 1. Rockall score, Glasgow-Blatchford score, AIMS65 score, and respective variables
Rockall scorea
0 1 2 3
Age <60 years 60–79 years ≥80 years
Shock “No shock”: SBP >100 mm 
Hg and HR <100 bpm
“Tachycardia”: SBP >100 
mm Hg and HR >100 bpm
“Hypotension”: SBP <100 mm 
Hg
Comorbidity IHD, CHF, any major 
comorbidity
Renal failure, liver 
failure, disseminated 
malignancy
Diagnosisb Mallory-Weiss tear or no 
lesion observed
Peptic ulcer disease,  
erosive esophagitis
Malignancy of UGI tract
Stigmata of recent 
hemorrhageb
Clean-based ulcer, flat  
pigmented spot
Blood in UGI tract, clot,  
visible vessel, bleeding
Glasgow-Blatchford scorec
0 1 2 3 4 6
Blood urea nitrogen, mg/dL <18.2 ≥18.2 to <22.4 ≥22.4 to <28 ≥28 to <70 ≥70
Hemoglobin, men, g/dL ≥13 ≥12 to <13 ≥10 to <12 <10
Hemoglobin, women, g/dL ≥12 ≥10 to <12 <10
Systolic blood pressure, mm Hg ≥110 ≥100 to <109 ≥90 to <99 <90
Other markers Pulse rate ≥100 bpm; 
melenad
Syncoped; hepatic  
diseased; heart failured
AIMS65 scoree
Albumin <3.0 g/dL 1
INR >1.5 1
Altered mental status 1
Systolic blood pressure <90 mm Hg 1
Age >65 years 1
SBP, systolic blood pressure; HR, heart rate; bpm, beats per minute; IHD, ischemic heart disease; CHF, congestive heart failure; UGI, 
upper gastrointestinal; INR, international normalized ratio. a Maximum score in the postendoscopic Rockall score: 11 points; maximum 
score in the pre-endoscopic Rockall score: 7 points. b Variables not included in the pre-endoscopic Rockall Score. c Maximum score in 
the original Glasgow-Blatchford score: 23 points; maximum score in the modified Glasgow-Blatchford score: 16 points. d Variables not 
included in the simplified Glasgow-Blatchford score. e Maximum score: 5 points.
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Clinical Outcomes
Seven important clinical outcomes in the setting of 
UGIB were evaluated. Blood transfusion was considered 
clinically necessary in almost three-quarters of the pa-
tients (321 patients; 74.1%). The median number of red 
blood cell units transfused was 2 (IQR: 0–4). Attending 
physicians considered the bleeding episode sufficiently 
severe to require a close monitoring in an intensive or in-
termediate care unit in 46.2% of the cases (200 patients). 
The remaining patients were admitted to a conventional 
ward, with the exception of 13 patients who were dis-
charged. The median length of hospital stay was 8 days 
(IQR: 6–11). During upper endoscopy, a therapeutic in-
tervention was performed in 169 patients (39.0%): 63 pa-
tients had a hemostatic procedure for variceal bleeding, 
while 106 patients had an intervention in the context of 
nonvariceal bleeding. Surgery was required as a rescue 
therapy in only 8 patients (1.8%). Two of the most impor-
tant outcomes that were analyzed were 30-day rebleeding 
and mortality, which occurred in 33 (7.6%) and in 32 
(7.4%) patients, respectively. From the patients who had 
rebleeding, only 6 died in the following 30 days. The me-
dian interval time from admission to rebleeding was 5.5 
days (IQR: 3.0–8.5), while death occurred averagely 11.5 
± 6.2 days after admission.
Comparison between Scores
When AUROCs of each score were compared, the 
sGBS and GBS were found to be the only scores that were 
good in predicting the need for blood transfusion, having 
AUROCs of 0.828 (95% CI: 0.774–0.882) and 0.826 (95% 
CI: 0.773–0.880), respectively. No statistical differences 
were found between them (p = 0.898). The 3 remaining 
scores were not useful in predicting this outcome. The 
sGBS and GBS were again the only scores that could fair-
ly predict the need for surgery for bleeding control, pre-
senting AUROCs of 0.736 (95% CI: 0.588–0.885) and 
0.706 (95% CI: 0.564–0.848), respectively. Once again, 
the sGBS performed as well as the GBS with no statisti-
cally significant differences found between them (p = 
0.529).
Any of the 5 compared scores were able to predict the 
remaining clinical intervention-related outcomes, such 
as admission to intermediate or intensive care unit, length 
of hospital stay longer than 1 week, and need for thera-
peutic endoscopic intervention. While 30-day rebleeding 
could not be accurately predicted by any of the studied 
scores, prediction of 30-day mortality was possible by the 
PreRS and PostRS, which presented AUROCs of 0.711 
(95% CI: 0.618–0.804) and 0.714 (95% CI: 0.623–0.805), 
Table 2. Baseline patient characteristics
Median age (IQR), years 67.8 (56.0–80.0)
Gender, n (%)
Male 281 (64.9)
Female 152 (35.1)
Symptoms at admission, n (%)
Melena 200 (46.2)
Hematemesis 188 (43.4)
Syncope 49 (11.3)
Hematemesis and melena 33 (7.6)
Hematochezia 12 (2.8)
Comorbidities, n (%)
Heart failure 95 (21.9)
Liver disease 85 (19.6)
Renal failure 35 (8.1)
Ischemic heart disease 34 (7.9)
Disseminated malignancy 15 (3.5)
Other major comorbidity 241 (55.7)
Medications, n (%)
Acetylsalicylic acid 120 (27.7)
Proton pump inhibitors 119 (27.5)
Nonsteroidal anti-inflammatory drugs 75 (17.3)
Anticoagulant agent 75 (17.3)
Antiplatelet agents 45 (10.4)
Steroids 24 (5.5)
Selective serotonin reuptake inhibitors 24 (5.5)
Physical findings, n (%)
Tachycardia 115 (26.6)
Shock 71 (16.4)
Altered mental status 41 (9.5)
Laboratory results, mean ± SD
Hemoglobin, g/dL 9.1±2.7
Urea, mg/dL 80.6±50.1
Albumin, g/dL 2.9±1.2
INR 1.6±1.2
Findings at endoscopy, n (%)
Gastric ulcer 73 (16.9)
Esophageal varices 66 (15.2)
Duodenal ulcer 64 (14.8)
Esophagitis 30 (6.9)
Gastritis 27 (6.2)
Mallory-Weiss tear 24 (5.5)
Neoplasia 22 (5.1)
Angiectasia 14 (3.2)
Gastric varices 10 (2.3)
Dieulafoy lesion 9 (2.1)
Gastric antral vascular ectasia 2 (0.5)
Cameron lesion 2 (0.5)
Portal hypertension gastropathy 1 (0.2)
Other sources 12 (2.8)
Normal endoscopy 77 (17.8)
IQR, interquartile range; SD, standard deviation; INR, 
international normalized ratio.
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respectively. No differences between them were found 
(p = 0.915). 
In this group of patients, the AIMS65 score was not 
able to accurately predict any of the 7 studied clinical out-
comes. A comparison between the ROC curves of the 5 
different scores in the abovementioned clinical outcomes 
can be seen in Figure 1. 
Discussion
Several recent guidelines on UGIB state that early risk 
stratification should be a cardinal step in the assessment 
of patients in the ED [4, 5]. The RS, the GBS, and more 
recently the AIMS65 score are some of the most used and 
cited scores. Nevertheless, since all available scores have 
some limitations and weaknesses that have not yet been 
overcome, the perfect risk score seems to be a long way 
away. In the meantime, a comparison between older risk 
scores, their simplified versions, and newer scores to as-
sess their individual ability to predict each outcome is es-
sential to guide evidence-based clinical decisions. While 
many authors have published studies comparing the old-
er PreRS, PostRS, and GBS, few comparative studies have 
included the sGBS and the recent AIMS65 score.
The PostRS has the disadvantage of requiring endo-
scopic data, which can delay the risk assessment, particu-
larly when after-hours emergency endoscopy is not avail-
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Fig. 1. ROC curve comparison of the PreRS, PostRS, GBS, sGBS, 
and AIMS65 for the prediction of blood transfusion (a), admission 
to the intermediate care unit (b), therapeutic endoscopic interven-
tion (c), surgery (d), 30-day rebleeding (e), and 30-day mortality 
(f). ROC, receiver operating characteristic; PreRS, pre-endoscopic 
Rockall score; PostRS, postendoscopic Rockall score; GBS, 
Glasgow-Blatchford score; sGBS, simplified version of the 
Glasgow-Blatchford score. 
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able, and also of including some difficult-to-define terms, 
namely “any major comorbidities,” which may affect the 
correct score calculation. Regarding RS-predictable out-
comes, while the initial study proposing the RS reported 
a good accuracy in predicting mortality and rebleeding 
[6], subsequent studies questioned its ability to predict 
rebleeding, suggesting the use of the RS for mortality pre-
diction only [12, 13]. This result was also observed in our 
study, in which the PostRS was good in predicting 30-day 
mortality but failed to predict rebleeding.
While a comparison of the PreRS and PostRS has been 
the common goal of many studies, the obtained results 
have been contradictory. While some authors suggested 
that the PreRS was not useful in predicting death when 
compared to the PostRS [14], others presented results ad-
mitting that the PreRS can be as good as the PostRS in 
predicting mortality [15, 16]. In our cohort of patients, 
the PreRS and PostRS were the only scores which could 
accurately predict 30-day mortality, exhibiting similar 
performances. This result is encouraging, suggesting that 
the PostRS may be replaced by the simpler PreRS.
Despite not requiring endoscopic data, the GBS has as 
well some features that may hamper its routine use in dai-
ly clinical practice. Firstly, it is composed of too many 
variables, with different weights, that might be difficult to 
recall in the stressful setting of the ED. Then, some of the 
included variables, in particular syncope, melena, hepatic 
disease, and heart failure, are subjective and ambiguous, 
potentially leading to an inaccurate and not always repro-
ducible classification of patients. Syncope, for example, 
which is often not witnessed by health-care professionals, 
may not be adequately reported by confused patients or 
by stressed relatives. On the other hand, melena, which is 
defined as black tarry stool, may be confused with the ex-
pected discoloration of feces in patients taking oral iron 
supplements or bismuth-containing medications. Still, 
concerning the definition of heart failure, it is question-
able if it should include only patients with decompensat-
ed disease or also with compensated disease or if there 
should be any established ejection fraction cutoff. Finally, 
regarding hepatic disease, it is dubious if only patients 
with signs of cirrhosis should be considered or if those 
with chronic liver disease but no signs of cirrhosis should 
be included as well. Regardless of these limitations, the 
GBS is of proven value in the initial assessment of patients 
with UGIB, and many studies have confirmed its capac-
ity to accurately predict the need for medical interven-
tion, even in specific subgroups of patients, such as cancer 
patients [7, 17, 18]. In our study, the GBS had a particu-
larly good accuracy in predicting the need for blood 
transfusion, which was superior to the PreRS, PostRS, 
and AIMS65. This finding is concordant with other stud-
ies [15, 16, 19] and might be explained by the fact that the 
GBS is the only score that uses hemoglobin for its calcula-
tion and because it is one of the most weighted variables 
within this score. As previously reported in other studies 
[15, 16], the GBS was also accurate in predicting the need 
for surgical treatment.
In order to facilitate the wide application of risk scores 
in the initial assessment of UGIB patients, a simplified 
version of the GBS has been proposed. Here, we aimed to 
analyze if the recently proposed sGBS had a performance 
similar to the original GBS. In the studied group of pa-
tients, we were able to confirm that, while overlapping 
with the GBS, the sGBS outperformed the PreRS, PostRS, 
and AIMS65 when predicting blood transfusion or sur-
gery. This result is again in accordance with other authors 
[9], reinforcing the potential role of this simplified ver-
sion when assessing a patient in the ED.
The AIMS65 score was recently created with the pur-
pose of overcoming some limitations of previous scores 
by including equally weighted and easy-to-recall vari-
ables. It showed a great accuracy in predicting mortality 
and length of hospital stay when used generally in the 
UGIB setting, independently of the etiology [8]. Howev-
er, some authors have questioned its usefulness in some 
particular subgroups of patients, namely those with pep-
tic ulcer [20]. This may be explained by the fact that 3 
from the 5 variables included in this score, such as albu-
min, mental status, and INR, are deeply associated with 
cirrhosis and variceal bleeding. While, in our study, the 
AIMS65 score has been the only score that could not ac-
curately predict any of the studied outcomes, some rea-
sons can be pointed out to explain this finding. First of all, 
serum albumin, unlike hemoglobin, urea, or INR, is not 
routinely analyzed in the ED of our center, precluding the 
calculation of the AIMS65 score in about one-quarter of 
the patients. Secondly, we included patients with both 
variceal and nonvariceal causes of bleeding, and, as stated 
before, the AIMS65 might be useless in some subgroups 
of patients. Finally, we reached some conclusions which 
are in accordance with other studies, namely the inability 
of the AIMS65 score to accurately predict blood transfu-
sion, rebleeding, or admission to the intensive/intermedi-
ate care unit [21].
Regarding UGIB, there is currently a growing interest 
in not only optimizing and simplifying the existing risk 
scores but also in creating new, more accurate ones. As an 
unique score applicable to all cases of UGIB, independent-
ly of the etiology, and capable of predicting with precision 
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all the relevant clinical outcomes is not yet available, we 
admit that the combination of a few simple risk scores 
might be useful for physicians assessing patients with 
UGIB in the ED, particularly when emergency endoscopy 
is not available on a 24-h basis. Bearing this idea in mind, 
we attempted to provide an easy-to-follow algorithm to 
readily guide decisions (Fig. 2). We propose that the initial 
calculation of the PreRS, which does not require endo-
scopic data, contains only 3 clinical parameters and can 
assess the risk of mortality as accurately as the PostRS. The 
definition of 2 as the cutoff allows this model to have a 
sensitivity of 93.9% and a negative predictive value of 
98.1%. The next step should be the calculation of the sGBS. 
This score has the advantage of abolishing the subjective 
parameters of the original GBS, such as syncope, melena, 
heart failure, and hepatic disease, while performing equal-
ly well in predicting medical intervention. Once again, the 
establishment of 2 as the cutoff allowed a high sensitivity 
(99.7%) and negative predictive value (87.5%). According 
to our proposed algorithm, the use of these 2 risk scores, 
the PreRS and the sGBS, should dictate the degree of med-
ical care and the time until upper endoscopy.
To the best of our knowledge, this is the first published 
study comparing the PreRS, PostRS, GBS, sGBS, and 
AIMS65 scores. We showed that none of the 5 studied 
scores can be singly used to predict the clinically relevant 
outcomes in the setting of UGIB: blood transfusion, en-
doscopic therapeutic intervention, surgery, admission to 
intensive/intermediate care unit, length of hospital stay, 
rebleeding, and death. The PreRS and PostRS were the 
only scores that could predict 30-day mortality. In addi-
tion, the sGBS is as precise as its original version in pre-
dicting blood transfusion and surgery. On the contrary, 
any of the 5 scores is sufficiently accurate in predicting 
endoscopic therapy or rebleeding. While a novel simpler 
score is not available and validated for the prediction of 
all outcomes in undifferentiated UGIB (either variceal or 
nonvariceal), we propose the concomitant use of the 
PreRS and sGBS as part of the initial assessment of these 
patients. 
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Fig. 2. Proposed algorithm for risk assessment in the upper gastrointestinal bleeding setting.
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